Colorectal Neoplasms

Oncology
37
Pipeline Programs
23
Companies
50
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
2
17
0
10
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1179%
Monoclonal Antibody
214%
Peptide
17%
+ 28 programs with unclassified modality

On Market (2)

Approved therapies currently available

Boehringer Ingelheim
OFEVApproved
nintedanib
Boehringer Ingelheim
oral2014
Bayer
STIVARGAApproved
regorafenib
Bayer
oral2012

Competitive Landscape

21 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
8 programs
1
4
2
1
Blood drawPhase 41 trial
Irinotecan + 5 FU + folinic acidPhase 31 trial
Modified Bolus 5-FU/LV with IrinotecanPhase 31 trial
CI-1040Phase 21 trial
EKB-569Phase 21 trial
+3 more programs
Active Trials
NCT05983133Active Not Recruiting65Est. Aug 2026
NCT00034827Completed172Est. May 2003
NCT00072748Completed63Est. Oct 2004
+5 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
8 programs
1
5
2
1
BI 695502Phase 31 trial
NintedanibPhase 3Small Molecule1 trial
BIBF 1120Phase 21 trial
BIBF 1120 and BIBW 2992Phase 21 trial
BIBH 1Phase 21 trial
+3 more programs
Active Trials
NCT02450656Unknown320Est. Dec 2019
NCT00904839Completed128Est. Jan 2012
NCT00801294Completed46
+5 more trials
Bayer
BayerLEVERKUSEN, Germany
4 programs
3
1
RegorafenibPhase 3Small Molecule1 trial
VatalanibPhase 3Small Molecule1 trial
VatalanibPhase 3Small Molecule1 trial
RegorafenibN/ASmall Molecule1 trial
Active Trials
NCT02656524Completed400Est. Feb 2017
NCT01853319Completed100Est. Jun 2018
NCT00056459Completed1,168
+1 more trials
Novartis
NovartisBASEL, Switzerland
3 programs
1
2
VatalanibPhase 3Small Molecule
VatalanibPhase 3Small Molecule
epothilone bPhase 21 trial
Active Trials
NCT00035087Completed62Est. Mar 2003
E
EisaiChina - Liaoning
1 program
1
pembrolizumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT04776148Completed563Est. Sep 2024
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
CPX-1Phase 21 trial
Active Trials
NCT00361842Completed65Est. Dec 2008
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
ErbituxPhase 21 trial
Active Trials
NCT00044863Completed250Est. Dec 2005
EpicentRx
EpicentRxCA - La Jolla
1 program
1
RRx-001Phase 21 trial
Active Trials
NCT02096354CompletedEst. Oct 2020
M&
Merck & Co.RAHWAY, NJ
1 program
1
TepotinibPhase 2Small Molecule5 trials
Active Trials
NCT05203822CompletedEst. Jul 2022
NCT05213481CompletedEst. May 2022
NCT04515394Terminated3Est. Mar 2022
+2 more trials
Oxford Biomedica
Oxford BiomedicaMA - Bedford
1 program
1
TroVaxPhase 21 trial
Active Trials
NCT00259844Completed20Est. Dec 2006
Plus Therapeutics
1 program
1
apatinibPhase 2Small Molecule1 trial
Active Trials
NCT03190616CompletedEst. Dec 2019
BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinationsPhase 21 trial
Active Trials
NCT04911517UnknownEst. Dec 2024
Transgene
TransgeneFrance - Illkirch-Graffenstaden
1 program
1
TG6002Phase 1/21 trial
Active Trials
NCT04194034TerminatedEst. Feb 2023
Dynavax Technologies
Dynavax TechnologiesCA - Emeryville
1 program
1
1018 ISS immunostimulatory oligonucleotidePhase 1Peptide1 trial
Active Trials
NCT00403052Terminated14Est. Dec 2007
DS
Daiichi SankyoChina - Shanghai
1 program
1
CS-1008Phase 11 trial
Active Trials
NCT01220999Completed19Est. Jun 2012
Providence Therapeutics
1 program
1
MEDI6469Phase 11 trial
Active Trials
NCT02559024TerminatedEst. Oct 2018
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
hMN14Phase 11 trial
Active Trials
NCT00041691Terminated30
EXACT Therapeutics
EXACT TherapeuticsNorway - Oslo
3 programs
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation TestingN/A1 trial
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical N/A1 trial
Stool Sample Collection KitN/A1 trial
Active Trials
NCT01600209Completed674Est. Sep 2012
NCT01260168Completed435Est. Nov 2013
NCT02503631Terminated397Est. Sep 2017
Genentech
GenentechCA - Oceanside
1 program
BevacizumabN/AMonoclonal Antibody1 trial
Active Trials
NCT00661154Completed7Est. Jul 2010
Design Therapeutics
1 program
Endocuff VisionN/A1 trial
Active Trials
NCT03072472CompletedEst. Feb 2018
Tabuk Pharmaceuticals
Tabuk PharmaceuticalsSaudi Arabia - Riyadh
1 program
Stool for Occult Blood Test and Colonoscopy with comprehensive medical checkupsN/A1 trial
Active Trials
NCT04875793CompletedEst. Jul 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerBlood draw
Eisaipembrolizumab
Boehringer IngelheimBI 695502
Boehringer IngelheimNintedanib
BayerRegorafenib
PfizerModified Bolus 5-FU/LV with Irinotecan
BayerVatalanib
BayerVatalanib
PfizerIrinotecan + 5 FU + folinic acid
PfizerEKB-569
BeOne Medicineslong course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations
Merck & Co.Tepotinib
Merck & Co.Tepotinib
Merck & Co.Tepotinib
Plus Therapeuticsapatinib

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 6,812 patients across 50 trials

NCT00140036PfizerBlood draw

Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).

Start: Sep 2002Est. completion: Aug 2005137 patients
Phase 4Completed
NCT04776148Eisaipembrolizumab

Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

Start: Mar 2021Est. completion: Sep 2024563 patients
Phase 3Completed
NCT02776683Boehringer IngelheimBI 695502

Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer

Start: Jun 2016Est. completion: Oct 2018123 patients
Phase 3Completed
NCT02149108Boehringer IngelheimNintedanib

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

Start: Sep 2014Est. completion: Aug 2016768 patients
Phase 3Completed
NCT01853319BayerRegorafenib

Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy

Start: Jul 2013Est. completion: Jun 2018100 patients
Phase 3Completed
NCT00101686PfizerModified Bolus 5-FU/LV with Irinotecan

Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.

Start: Feb 2003Est. completion: Oct 2008547 patients
Phase 3Completed
NCT00056459BayerVatalanib

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

Start: Feb 20031,168 patients
Phase 3Completed
NCT00056446BayerVatalanib

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

Start: Jan 2003Est. completion: Jan 2007855 patients
Phase 3Completed
NCT00143403PfizerIrinotecan + 5 FU + folinic acid

Comparing Irinotecan and 5 FU/FA To 5-FU/FA After Resection Of Liver Metastases For Colorectal Cancer

Start: Dec 2001Est. completion: Sep 2009321 patients
Phase 3Completed
NCT00072748PfizerEKB-569

Study Evaluating EKB-569 in Advanced Colorectal Cancer

Est. completion: Oct 200463 patients
Phase 2Completed
NCT04911517BeOne Medicineslong course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations

Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.

Start: Jun 2021Est. completion: Dec 2024
Phase 2Unknown
NCT04515394Merck & Co.Tepotinib

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Start: Jan 2021Est. completion: Mar 20223 patients
Phase 2Terminated
NCT04647838Merck & Co.Tepotinib

Tepotinib in Solid Tumors Harboring MET Alterations

Start: Jan 2020Est. completion: Aug 2024
Phase 2Unknown
NCT03940703Merck & Co.Tepotinib

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Start: Sep 2019Est. completion: May 2026
Phase 2Active Not Recruiting
NCT03190616Plus Therapeuticsapatinib

Apatinib in Refractory Colorectal Cancer

Start: Jul 2017Est. completion: Dec 2019
Phase 2Completed
NCT02864992Merck & Co.Tepotinib

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Start: Sep 2016Est. completion: Apr 2026
Phase 2Active Not Recruiting
NCT02780700Boehringer IngelheimNintedanib

Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]

Start: Jul 2016Est. completion: Sep 20161 patients
Phase 2Terminated
NCT02096354EpicentRxRRx-001

A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Start: May 2014Est. completion: Oct 2020
Phase 2Completed
NCT01152437Boehringer IngelheimBIBW 2992

A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer

Start: Jun 201094 patients
Phase 2Completed
NCT00904839Boehringer IngelheimBIBF 1120

BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer

Start: May 2009Est. completion: Jan 2012128 patients
Phase 2Completed
NCT00361842Jazz PharmaceuticalsCPX-1

Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer

Start: Jul 2006Est. completion: Dec 200865 patients
Phase 2Completed
NCT00801294Boehringer IngelheimBIBF 1120 and BIBW 2992

A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer

Start: Jul 200646 patients
Phase 2Completed
NCT00259844Oxford BiomedicaTroVax

Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed

Start: Jun 2004Est. completion: Dec 200620 patients
Phase 2Completed
NCT00078468PfizerPELITREXOL/AG-2037

Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment

Start: Dec 2003Est. completion: Sep 200456 patients
Phase 2Completed
NCT00044863Eli Lilly and CompanyErbitux

Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma

Start: Aug 2002Est. completion: Dec 2005250 patients
Phase 2Completed
NCT00040391PfizerInvestigational drug

A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

Start: Jun 2002
Phase 2Terminated
NCT00035087Novartisepothilone b

EPO906 Therapy in Patients With Advanced Colorectal Cancer

Start: May 2002Est. completion: Mar 200362 patients
Phase 2Completed
NCT00034827PfizerCI-1040

A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer

Start: Jan 2002Est. completion: May 2003172 patients
Phase 2Completed
NCT02198274Boehringer IngelheimBIBH 1

Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer

Start: Feb 200025 patients
Phase 2Completed
NCT04194034TransgeneTG6002

Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer

Start: Jan 2020Est. completion: Feb 2023
Phase 1/2Terminated
NCT02450656Boehringer IngelheimAfatinib

Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer

Start: Jun 2015Est. completion: Dec 2019320 patients
Phase 1/2Unknown
NCT02115373Merck & Co.Tepotinib

c-Met Second-Line Hepatocellular Carcinoma

Start: May 2014Est. completion: Feb 2018
Phase 1/2Completed
NCT01982955Merck & Co.Tepotinib

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Start: Dec 2013Est. completion: Oct 2021
Phase 1/2Completed
NCT00041691Gilead ScienceshMN14

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery

30 patients
Phase 1Terminated
NCT05983133PfizerPF-08046052

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Start: Nov 2023Est. completion: Aug 202665 patients
Phase 1Active Not Recruiting
NCT05203822Merck & Co.Tepotinib

Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants

Start: Jan 2022Est. completion: Jul 2022
Phase 1Completed
NCT05213481Merck & Co.Tepotinib

Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants

Start: Dec 2021Est. completion: May 2022
Phase 1Completed
NCT04204902Merck & Co.Tepotinib

Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib

Start: Oct 2019Est. completion: Dec 2019
Phase 1Completed
NCT03629223Merck & Co.Tepotinib

Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib

Start: Aug 2018Est. completion: Jan 2019
Phase 1Completed
NCT03628339Merck & Co.Tepotinib

Effect of Tepotinib on PK of CYP3A Substrate Midazolam

Start: Aug 2018Est. completion: Oct 2018
Phase 1Completed
NCT03546608Merck & Co.Tepotinib

Tepotinib Hepatic Impairment Trial

Start: Jun 2018Est. completion: Feb 2019
Phase 1Completed
NCT03531762Merck & Co.Tepotinib

Effect of a Proton Pump Inhibitor on the PK of Tepotinib

Start: May 2018Est. completion: Jul 2018
Phase 1Completed
NCT02559024Providence TherapeuticsMEDI6469

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

Start: Mar 2016Est. completion: Oct 2018
Phase 1Terminated
NCT03021642Merck & Co.Tepotinib

Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers

Start: Jan 2016Est. completion: Mar 2016
Phase 1Completed
NCT01220999Daiichi SankyoCS-1008

A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

Start: Oct 2010Est. completion: Jun 201219 patients
Phase 1Completed
NCT00403052Dynavax Technologies1018 ISS immunostimulatory oligonucleotide

A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer

Start: Nov 2006Est. completion: Dec 200714 patients
Phase 1Terminated
NCT04875793Tabuk PharmaceuticalsStool for Occult Blood Test and Colonoscopy with comprehensive medical checkups

Effectiveness of an Integrated Colorectal Cancer Screening in Saudi Arabia: A Pragmatic Randomized Trial

Start: Jun 2021Est. completion: Jul 2022
N/ACompleted
NCT03072472Design TherapeuticsEndocuff Vision

BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities

Start: Feb 2017Est. completion: Feb 2018
N/ACompleted
NCT02656524BayerRegorafenib

Stivarga Real Life Evidence in Hungary

Start: Jul 2016Est. completion: Feb 2017400 patients
N/ACompleted
NCT02503631EXACT TherapeuticsStool Sample Collection Kit

Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers

Start: Oct 2014Est. completion: Sep 2017397 patients
N/ATerminated

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2m ago

Office Administrator

SystImmune
2m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
12m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
16m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
16m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

10 late-stage (Phase 3) programs — potential near-term approvals
23 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)